IP Library › Granted Patent US 9,914,909
Granted Patent B2
US 9,914,909 · App. 15/167,869 · Granted Mar 13, 2018

Costimulatory chimeric antigen receptor T cells targeting IL13Rα2

Inventors: Christine E. Brown (Duarte, CA); Stephen J. Forman (Duarte, CA)
Assignee: City of Hope
C12N5/0636A61K35/17C07K14/5437C07K14/7051C07K14/70514C07K14/70578C07K14/7155A61K38/00C07K2319/03C07K2319/30C07K2319/33C07K2319/74C07K2319/75C12N2510/00C12N2740/16043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,914,909
App. No.
15/167,869
Granted
Mar 13, 2018
Kind
B2
Abstract

Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes IL-13 or a variant thereof that binds interleukin-13Rα2 (IL13Rα2), a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.

Claims (16)

1. A nucleic acid molecule comprising a nucleotide sequence encoding a chimeric antigen receptor molecule comprising the amino acid sequence of SEQ ID NO: 10.

2. An expression vector comprising the nucleic acid molecule of claim 1 .

3. The expression vector of claim 2 wherein the expression vector is a lentiviral vector.

4. The nucleic acid molecule of claim 1 further comprising a nucleotide sequence encoding a GMSCFRa signal sequence preceding the nucleotide sequence encoding the chimeric antigen receptor.

5. The nucleic acid molecule of claim 4 wherein the GMSCFRa signal sequence comprises the amino acid sequence of SEQ ID NO:2.

6. The nucleic acid molecule of claim 4 further comprising a nucleotide sequence encoding a T2A ribosome skip sequence following the nucleotide sequence encoding the chimeric antigen receptor.

7. The nucleic acid molecule of claim 6 wherein T2A ribosome skip sequence comprises the amino acid sequence of SEQ ID NO:8.

8. An expression vector comprising the nucleic acid molecule of claim 4 .

9. The expression vector of claim 8 wherein the expression vector is a lentiviral vector.

10. The nucleic acid molecule of claim 1 further comprising a nucleotide sequence encoding a T2A ribosome skip sequence following the nucleotide sequence encoding the chimeric antigen receptor.

11. The nucleic acid molecule of claim 10 wherein T2A ribosome skip sequence comprises the amino acid sequence of SEQ ID NO:8.

12. The nucleic acid molecule of claim 10 further comprising a nucleotide sequence encoding a truncated CD19 following the nucleotide sequence encoding the T2A ribosome skip sequence.

13. The nucleic acid molecule of claim 12 wherein the truncated CD19 comprises the amino acid sequence of SEQ ID NO:9.

14. The nucleic acid molecule of claim 12 wherein the truncated CD19 consists of the amino acid sequence of SEQ ID NO:9.

15. The nucleic acid molecule of claim 1 further comprising a nucleotide sequence encoding a truncated CD19.

16. The nucleic acid molecule of claim 15 wherein the truncated CD19 comprises the amino acid sequence of SEQ ID NO:9.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2017
From: CITY OF HOPE NATIONAL MEDICAL CENTER
To: CITY OF HOPE
Reel/Frame 042620/0821 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2016
From: BROWN, CHRISTINE E.; FORMAN, STEPHEN J.
To: CITY OF HOPE NATIONAL MEDICAL CENTER
Reel/Frame 038748/0543 →
Continuity (3)
Continuation PCTUS2015051089 · Sep 18, 2015
Provisional Application 62053068 · Sep 19, 2014
Related Publication 20160340649A1 · Nov 24, 2016